Literature DB >> 1005912

Tissue distribution of bovine 125I-superoxide dismutase in mice.

A Petkau, W S Chelack, K Kelly, C Barefoot, L Monasterski.   

Abstract

Intravenously injected 125I-bovine superoxide dismutase in mice is essentially cleared from organs in 24 h. The 125I activity per g of tissue at 1 h varies among organs with the brain and kidneys showing the lowest and highest levels, respectively. Within tissues, degradation occurs so that, at 1 h after administration, 5-74% of the 125I activity remains associated with the enzyme, depending on the tissue. A small amount of the labelled enzyme is found in washed cells of thymus, lung, spleen, liver and brain.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1005912

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  7 in total

1.  The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase.

Authors:  Erin G Rosenbaugh; James W Roat; Lie Gao; Rui-Fang Yang; Devika S Manickam; Jing-Xiang Yin; Harold D Schultz; Tatiana K Bronich; Elena V Batrakova; Alexander V Kabanov; Irving H Zucker; Matthew C Zimmerman
Journal:  Biomaterials       Date:  2010-04-07       Impact factor: 12.479

2.  Potentiation of acute paraquat toxicity by vitamin E deficiency.

Authors:  E R Block
Journal:  Lung       Date:  1979       Impact factor: 2.584

3.  Interaction between superoxide dismutase and dipalmitoylphosphotidylglycerol bilayers: a fourier transform infrared (FT-IR) spectroscopic study.

Authors:  Y L Lo; Y E Rahman
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

4.  Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase gene expression by CuZn superoxide dismutase in human fibroblasts and HepG2 cells.

Authors:  Bruna De Felice; Mariarosaria Santillo; Rosalba Serù; Simona Damiano; Gianfranco Matrone; Robert Roy Wilson; Paolo Mondola
Journal:  Gene Expr       Date:  2004

Review 5.  Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.

Authors:  Erin G Rosenbaugh; Krupa K Savalia; Devika S Manickam; Matthew C Zimmerman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-03       Impact factor: 3.619

6.  Modifiers of free radicals inhibit in vitro the oncogenic actions of x-rays, bleomycin, and the tumor promoter 12-O-tetradecanoylphorbol 13-acetate.

Authors:  C Borek; W Troll
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  Phorbol ester inhibits phosphatidylserine synthesis in human promyelocytic leukaemia HL60 cells. Possible involvement of free radicals and correlation with phosphorylation of nuclear protein 1b.

Authors:  Z Kiss; E Deli; J F Kuo
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.